Description
Description
This page contains brief details about the drug ibrutinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
The U.S. FDA approved Ibrutinib as the first Bruton tyrosine kinase inhibitor (BTK) to treat several types of blood cancers on 13th November 2013.
Mechanism of Action of Ibrutinib
Ibrutinib Capsule is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a Bruton tyrosine kinase inhibitor belonging to the class of kinase inhibitors. Bruton tyrosine kinase is a protein that acts as a driving force for chronic lymphocytic leukemia and other B cell cancers. Ibrutinib acts against the enzymatic activity of BTK, further inhibiting its signaling. Thus, the number of cancer cells reduces and results in a delay in disease progression.
Uses of Ibrutinib
Ibrutinib Capsule has been developed to treat several types of blood cancers, such as Chronic lymphocytic leukemia (CLL), Mantle cell lymphoma, Waldenstrom’s macroglobulinemia, small lymphocytic lymphoma (SLL) and chronic graft versus host disease.
Ibrutinib Dosage available
The recommended dose of Ibrutinib is one capsule a day. Ibrutinib is available as a 140mg capsule. Swallow the entire capsule with water and do not open, dissolve or chew them. Take the capsule at the same time each day with food or between meals. Your physician will choose the dosage and administration frequency based on your medical condition because it differs for each person.
